ConvaTec Group’s (CTEC) Outperform Rating Reaffirmed at Citigroup

Citigroup reissued their outperform rating on shares of ConvaTec Group (LON:CTEC) in a research note issued to investors on Thursday morning, Marketbeat.com reports. Citigroup currently has a GBX 315 price target on the stock.

Several other analysts also recently commented on CTEC. Berenberg Bank increased their target price on shares of ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a report on Thursday, January 22nd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a research note on Friday, November 14th. UBS Group reissued a “buy” rating and set a GBX 375 target price on shares of ConvaTec Group in a research report on Friday, November 7th. Finally, Peel Hunt reaffirmed an “add” rating and issued a GBX 270 target price on shares of ConvaTec Group in a report on Thursday, November 13th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of GBX 319.57.

ConvaTec Group Trading Down 0.1%

Shares of ConvaTec Group stock opened at GBX 248.40 on Thursday. The company has a market capitalization of £4.84 billion, a P/E ratio of 23.43, a price-to-earnings-growth ratio of 0.93 and a beta of 0.76. The stock has a fifty day simple moving average of GBX 235.85 and a 200 day simple moving average of GBX 236.62. ConvaTec Group has a 12-month low of GBX 209.40 and a 12-month high of GBX 311.20. The company has a current ratio of 1.53, a quick ratio of 0.96 and a debt-to-equity ratio of 106.19.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.